Therapeutic Effect of Dietary Omega-6 and Omega-3 Fatty Acids in Improving Social Impairment in Youth With Autism Spectrum Disorders: A Double-Blind, Randomized, Placebo-Controlled Trial

INTERVENTION: Intervention type:DRUG. Intervention1:Aravita, Dose form:CAPSULE, Route of administration:ORAL, intended dose regimen:6 capsules per day. Control intervention1:Placebo (olive oil), Dose form:CAPSULE, Route of administration:ORAL, Intended dose regimen:6 capsules per day. CONDITION: Autism Spectrum Disorders including autism and Asperger disorder PRIMARY OUTCOME: Abberant Behavior Cheklist‐community (ABC‐C)?Social Responsiveness Scale (SRS). Timepoint:At every 4 weeks during 16‐week treatment. SECONDARY OUTCOME: Social Interaction and repetitive, stereotyped pattern of behavior and interest subscales of Autism Diagnostic Interview‐revised (ADI‐R). Timepoint: Before treatment and at every 4 weeks during 16‐week trial. INCLUSION CRITERIA: 13 individuals who met DSM‐IV‐R criteria for high functioning autistic disorder or Asperger's Disorder, corroborated by the Autism Diagnostic Interview‐Revised. Participants were free of any medical or comorbid psychiatric disorders. Other inclusion criteria included either a verbal or performance intelligence quotient above 80, and a score greater than 10 on the social withdrawal subscale of the Aberrant Behavior Checklist‐Community (ABC)